Splenomegaly: Difference between revisions
Line 85: | Line 85: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Dark urine | | align="center" style="background:#F5F5F5;" | | ||
* Dark urine | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Pancytopenia | * Pancytopenia | ||
Line 173: | Line 174: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Dark urine | | align="center" style="background:#F5F5F5;" | | ||
* Dark urine | |||
| align="center" style="background:#F5F5F5;" |NA | | align="center" style="background:#F5F5F5;" |NA | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 195: | Line 197: | ||
* HIV | * HIV | ||
* Autoimmune diseases | * Autoimmune diseases | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 242: | Line 244: | ||
* History of [[chemotherapy]] and[[ionizing radiation]] | * History of [[chemotherapy]] and[[ionizing radiation]] | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
Line 288: | Line 290: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
Line 305: | Line 307: | ||
* Lymphadenopathy | * Lymphadenopathy | ||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
| align="center" style="background:#F5F5F5;" |High ferritin | | align="center" style="background:#F5F5F5;" |High ferritin | ||
Line 335: | Line 337: | ||
* [[Radiation therapy|Radiation]] | * [[Radiation therapy|Radiation]] | ||
* Pre-existent blood disorders | * Pre-existent blood disorders | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 371: | Line 373: | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL'' | |||
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, female > male | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Vascular occlusive events and [[Bleeding|hemorrhages]] | |||
| align="center" style="background:#F5F5F5;" |± | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Flushing | |||
* Erythromelalgia | |||
* Transient ischemic attacks | |||
* Priapism | |||
* Decreased visual acuity | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Increased cellularity | |||
* Hyperplasia and clustering of megakaryocytes | |||
* Bone marrow reticulin may be increased with no collagen fibrosis | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Splenomegaly on abdominal CT | |||
* [[VTE]] on spiral chest CT | |||
* [[Deep vein thrombosis|DVT]] on ultrasound | |||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Thrombo-hemorrhagic complications | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Bone marrow]] fibrosis | |||
* [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL'' | |||
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, male> female | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Other [[Myeloproliferative neoplasm|myeloproliferative]]<nowiki/>disorders | |||
* [[Radioactive contamination|Radiation exposure]] | |||
* Chemicals exposure | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |– | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Pallor]] | |||
* [[Bruising]] | |||
* [[Nodules|Skin nodules]] | |||
* [[Nodules|Insert paragraph]] | |||
* [[Fatigue]] | |||
* [[Abdominal pain]] | |||
* [[Nodules|Early satiety]] | |||
* [[Dyspnea]] | |||
* [[Lymphadenopathy]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↑/↓ | |||
| align="center" style="background:#F5F5F5;" |Low iron | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Dark urine | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Proliferation and atypia of [[megakaryocytes]] | |||
* Reticulin or [[Collagen|collagen fibrosis]] | |||
* Hypercellular [[bone marrow]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Diffuse bone [[sclerosis]] on [[CT angiography|CT]] | |||
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]] | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Thrombo-hemorrhagic complications | |||
* Variable risk for development of [[acute leukemia]] | |||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref> | ||
Line 452: | Line 490: | ||
! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref> | ! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Bone marrow]]<nowiki/>infiltration | |||
* Ineffective [[hematopoiesis]] | |||
* Immune mediated | |||
| align="center" style="background:#F5F5F5;" |Any, more in adults | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Exposure to chemicals | |||
* [[Radiation therapy|Radiation]] | |||
* Pre-existent blood disorders | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" | + | |||
| align="center" style="background:#F5F5F5;" |+ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Nl | |||
| align="center" style="background:#F5F5F5;" |± | |||
| align="center" style="background:#F5F5F5;" |± | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Petechia|Petechiae]] | |||
* [[Muscle weakness|Weakness]] | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |↓ | |||
| align="center" style="background:#F5F5F5;" |Low iron, high ferritin | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" |↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Dark urine | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Blast cells | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |Biopsy | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Tumor lysis syndrome]] | |||
* [[Infection]] | |||
* [[CNS]] involvement | |||
| | * [[Disseminated intravascular coagulation|DIC]] | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category |
Revision as of 19:16, 29 September 2018
WikiDoc Resources for Splenomegaly |
Articles |
---|
Most recent articles on Splenomegaly Most cited articles on Splenomegaly |
Media |
Powerpoint slides on Splenomegaly |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Splenomegaly at Clinical Trials.gov Clinical Trials on Splenomegaly at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Splenomegaly
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Splenomegaly Discussion groups on Splenomegaly Patient Handouts on Splenomegaly Directions to Hospitals Treating Splenomegaly Risk calculators and risk factors for Splenomegaly
|
Healthcare Provider Resources |
Causes & Risk Factors for Splenomegaly |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Gichoya Judy Wawira [2], Moi University School of Medicine
Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Splenomegaly from Other Diseases
Category | Disease | Etiology | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | Lab Findings | Imaging | ||||||||||||||||||||||
Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | CBC | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | |||||||||||
WBC | Hb | Plt | |||||||||||||||||||||||||
Congestive | Cirrhosis[1] |
|
Any, more in elderly | – | + | ↑↓ | + | + | ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
|
|
Liver biopsy |
| ||
Heart failure[2] |
|
Elderly |
|
– | + | ↑↓ | – | – | ↑ | ↑ | ± | + |
|
↓ | ↓ | ↑ | Nl | ↑ | ↑ | ↑ | Nl | NA |
|
Echocardiography |
| ||
Thrombosis of portal, hepatic, or splenic veins[3] |
|
Any |
|
+ | + | ↑ | + | + | ↓ | Nl | ± | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA |
|
Doppler ultrasonography |
| ||
Malignancy | Lymphoma[4] |
|
Any |
|
+ | + | ↓ | + | + | Nl | Nl | + | – |
|
↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
|
Lymph node biopsy |
| |
Leukemia[5] |
|
Elderly, male>female |
|
+ | + | ↓ | + | + | Nl | Nl | ± | + |
|
↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
NA | Bone marrow examination + clinical manifestation |
| ||
Polycythemia Vera[6] |
|
Mean age >60 years old |
|
– | + | Nl | + | – | Nl | Nl | – | – |
|
Nl to ↑ | ↑ | Nl to ↑ | High ferritin | Nl | Nl | Nl | Nl |
|
NA | WHO criteria for PV | |||
Multiple myeloma[7] |
|
Any, more in adults |
|
+ | + | ↓ | + | + | Nl | Nl | + | – |
|
↓ | ↓ | ↓ | High ferritin | Nl | ↑ | ↑ |
|
|
Bone marrow examination |
| |||
Essential thrombocythemia[8] |
|
Mean age >60 years old, female > male |
|
± | + | Nl | + | + | Nl | Nl | – | – |
|
↑ | ↑ | ↑↑ | Nl | Nl | Nl | Nl | Nl |
|
Bone marrow biopsy |
| |||
Primary myelofibrosis[9] |
|
Mean age >60 years old, male> female |
|
– | + | Nl | + | + | Nl | Nl | + | – | ↓ | ↓ | ↑/↓ | Low iron | Nl | ↑ | Nl |
|
|
Bone marrow biopsy |
| ||||
Primary splenic tumors[10] | |||||||||||||||||||||||||||
Metastatic solid tumors[11] |
|
Any, more in adults |
|
+ | + | ↓ | + | + | ↓ | Nl | ± | ± | ↓ | ↓ | ↓ | Low iron, high ferritin | ↑ | ↑ | ↑ |
|
|
Biopsy |
| ||||
Category | Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Infection | Viral | Hepatitis | |||||||||||||||||||||||||
Infectious mononucleosis | |||||||||||||||||||||||||||
Cytomegalovirus | |||||||||||||||||||||||||||
Bacterial | Salmonella | ||||||||||||||||||||||||||
Brucella | |||||||||||||||||||||||||||
Tuberculosis | |||||||||||||||||||||||||||
Parasitic | Malaria | ||||||||||||||||||||||||||
Schistosomiasis | |||||||||||||||||||||||||||
Toxoplasmosis | |||||||||||||||||||||||||||
Kala-azar | Visceral leishmaniasis | ||||||||||||||||||||||||||
Infective endocarditis | |||||||||||||||||||||||||||
Fungal | |||||||||||||||||||||||||||
Inflammation | Sarcoidosis | ||||||||||||||||||||||||||
Serum sickness | |||||||||||||||||||||||||||
Systemic lupus erythematosus | |||||||||||||||||||||||||||
Felty syndrome | |||||||||||||||||||||||||||
Category | Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Infiltrative | Gaucher disease[12] | ||||||||||||||||||||||||||
Niemann-Pick disease | |||||||||||||||||||||||||||
Amyloidosis | |||||||||||||||||||||||||||
Langerhans cell histiocytosis | |||||||||||||||||||||||||||
Hemophagocytic lymphohistiocytosis | |||||||||||||||||||||||||||
Rosai-Dorfman disease | |||||||||||||||||||||||||||
Hematologic (hypersplenic) states | Hemolytic anemia | ||||||||||||||||||||||||||
Sickle cell disease | |||||||||||||||||||||||||||
Granulocyte colony-stimulating factor |
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Treatment
Case Studies
Related Chapters
References
- ↑ Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
- ↑ Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
- ↑ Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
- ↑ Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
- ↑ Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
- ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
- ↑ Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
- ↑ Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
- ↑ Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
- ↑ Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
- ↑ Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.